我国食管癌临床分期现状与思考  

Current Status of Clinical Staging for Esophageal Cancer in China

作　　者：尤鑫[1] 祝淑钗[2] 

机构地区：[1]河北医科大学,河北石家庄050000 [2]河北医科大学第四医院,河北石家庄050000

出　　处：《中国肿瘤》2014年第5期389-393,共5页China Cancer

摘　　要：食管癌分期是临床选择治疗方案、评估患者预后及评价治疗效果的重要参考依据,有效、实用的分期标准一直是研究的热点。虽然基于术后病理的UICC分期被公认为"金标准",但对于评价非手术食管癌患者其适用性明显受限。目前我国常用的临床分期主要有祝氏分期、协作组分期和食管癌GTV体积分期,三种分期的T、N、M定义标准不一。虽然其有效性得到部分学者的验证,但在临床实践中仍发现一些问题,准确性尚不如病理分期。全文就目前国内食管癌临床分期的发展进程及研究现状进行综述。Esophageal cancer stage is the important reference basis on the choice of treat- ment,prognosis assessment and therapeutic effect evaluation.Effective and practical staging standard is always the research hot spot. Although the UICC stage is determined based on the postoperative pathology and recognized as the ＂gold standard＂ , but for the non-surgery esophageal cancer patients, its applicability obviously is limited. At present, domestic common- ly used clinical staging is mainly Zhu＇s staging,cooperation group staging and esophageal cancer GTV staging. The three staging have different standards with T,N,M. Although their effectiveness have validated by some scholars,but aslo some problems in clinical practice were found, and their accuracy is not as good as the pathological staging. In this paper, the devel- opment process and research status of esophageal cancer clinical staging in China are re- viewed.

关 键 词：食管癌 临床分期 预后评价 

分 类 号：R735.1[医药卫生—肿瘤]